Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -65.59% is in line with its 5-year average of -62.40%, around the middle of its 5-year range (-123.60%–-25.59%).
As of the fiscal period ended Tuesday, June 30, 2026. 19.19% above its 12-month average of -81.16%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -65.59%.
RETURN ON EQUITY (ROE)
-65.59%
RETURN ON EQUITY (ROE) AVG TTM
-81.16%
RETURN ON EQUITY (ROE) AVG 3Y
-74.72%
RETURN ON EQUITY (ROE) AVG 5Y
-62.40%
RETURN ON EQUITY (ROE) AVG 10Y
-68.50%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+19.19%
CURRENT VS 3Y AVG
+12.22%
CURRENT VS 5Y AVG
-5.11%
CURRENT VS 10Y AVG
+4.25%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-56.12%
vs the sector median at left
Profound Medical Corp.
Market Cap
$220.93M
Return on Equity (ROE)
-65.59%
TTM Avg
-81.16%
3Y Avg
-74.72%
5Y Avg
-62.40%
Market Cap
$218.30M
Return on Equity (ROE)
-31.70%
TTM Avg
-2.04%
3Y Avg
-21.96%
5Y Avg
-21.56%
Market Cap
$216.91M
Return on Equity (ROE)
-45.23%
TTM Avg
-120.85%
3Y Avg
-88.04%
5Y Avg
-69.68%
Market Cap
$225.24M
Return on Equity (ROE)
-43.11%
TTM Avg
-35.75%
3Y Avg
-28.47%
5Y Avg
-12.53%
Market Cap
$215.07M
Return on Equity (ROE)
21.24%
TTM Avg
17.52%
3Y Avg
32.51%
5Y Avg
46.01%
Market Cap
$214.46M
Return on Equity (ROE)
-36.64%
TTM Avg
6.57%
3Y Avg
27.96%
5Y Avg
27.96%
Market Cap
$227.60M
Return on Equity (ROE)
-303.61%
TTM Avg
612.49%
3Y Avg
-57.80%
5Y Avg
-87.69%
Market Cap
$214.24M
Return on Equity (ROE)
19.38%
TTM Avg
20.63%
3Y Avg
-8.44%
5Y Avg
-40.10%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Profound Medical Corp. (PROF) | $220.93M | -65.59% | -81.16% | -74.72% | -62.40% |
| Keros Therapeutics, Inc. (KROS)vs › | $218.30M | -31.70% | -2.04% | -21.96% | -21.56% |
| Prelude Therapeutics Incorporated (PRLD)vs › | $216.91M | -45.23% | -120.85% | -88.04% | -69.68% |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $225.24M | -43.11% | -35.75% | -28.47% | -12.53% |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $215.07M | 21.24% | 17.52% | 32.51% | 46.01% |
| Sionna Therapeutics, Inc. (SION)vs › | $214.46M | -36.64% | 6.57% | 27.96% | 27.96% |
| Biodesix, Inc. (BDSX)vs › | $227.60M | -303.61% | 612.49% | -57.80% | -87.69% |
| Niagen Bioscience Inc (NAGE)vs › | $214.24M | 19.38% | 20.63% | -8.44% | -40.10% |
| Vogenx Inc. (VOGX)vs › | $227.91M | N/A | N/A | N/A | N/A |
| Lyell Immunopharma, Inc. (LYEL)vs › | $210.98M | -106.27% | -100.08% | -64.49% | -52.22% |
ROE
-65.6%
ROA
-52.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -65.59% |
| 2026-03-31 | -65.08% |
| 2025-12-31 | -46.79% |
| 2025-09-30 | -123.60% |
| 2025-06-30 | -104.74% |
| 2025-03-31 | -63.68% |
| 2024-12-31 | -46.67% |
| 2024-09-30 | -110.56% |
| 2024-06-30 | -56.89% |
| 2024-03-31 | -50.25% |
| 2023-12-31 | -75.55% |
| 2023-09-30 | -85.15% |
| 2023-06-30 | -76.80% |
| 2023-03-31 | -66.77% |
| 2022-12-31 | -69.16% |
| 2022-09-30 | -60.14% |
| 2022-06-30 | -53.82% |
| 2022-03-31 | -50.72% |
| 2021-12-31 | -45.77% |
| 2021-09-30 | -28.28% |
| 2021-06-30 | -25.59% |
| 2021-03-31 | -21.67% |
| 2020-12-31 | -14.47% |
| 2020-09-30 | -14.51% |
| 2020-06-30 | -36.55% |
| 2020-03-31 | -35.15% |
| 2019-12-31 | -116.73% |
| 2019-09-30 | -89.77% |
| 2019-06-30 | -95.99% |
| 2019-03-31 | -76.56% |
| 2018-12-31 | -59.37% |
| 2018-09-30 | -53.79% |
| 2018-06-30 | -51.93% |
| 2018-03-31 | -42.54% |
| 2017-12-31 | -146.38% |
| 2017-09-30 | -100.91% |
| 2017-06-30 | -253.15% |
| 2017-03-31 | -153.27% |
| 2016-12-31 | -121.71% |
| 2016-09-30 | -513.13% |
| 2016-06-30 | -209.20% |
| 2016-03-31 | -195.50% |
| 2015-12-31 | -89.85% |
| 2015-09-30 | -85.83% |
| 2015-06-30 | -48.44% |
| 2015-03-31 | -430.67% |
| 2014-12-31 | -321.18% |
